Schizophrenia/Psychosis

In comparison to the classic presentation of schizophrenia, ANMDARE features a later age of onset, female predominance, visual hallucinations, relative lack of cognitive disorganization, and a lack of an extended prodromal period.

The role of the oropharyngeal microbiome in schizophrenia and mania.

The biggest challenge we have faced thus far has been a three-fold rise in requests for assistance in managing persistent delirium. Needless to say, we are not twiddling our thumbs.

A nationwide cohort study sought to determine the clinical course of schizophrenia in women and men in order to improve diagnostic accuracy and design guidelines.

The role of neuroimaging is to rule out medically or surgically treatable causes of illness, such as new-onset psychosis.

When the patient has significant comorbid psychiatric problems, high risk of suicide, and Huntington disease, the role of clinician spills over into patient advocate in a complex medical system.

With adequate clinician awareness and prompt initiation of diagnostic testing and intervention, patients with autoimmune encephalitis can lead productive lives. A range of tests is described here.

Clinicians should keep in mind the risk-to-benefit ratio considerations before initiating polypharmacy, especially if they have patients with prescriptions inherited from several sources. Here: A summary of recommendations about the use of polypharmacy in psychotic disorders.

Patients with schizophrenia often have worse outcomes than their peers without the diagnosis. How you can support your patient in ensuring a better cancer prognosis?

There is evidence in both patients with psychotic disorders and the general population that cannabis use is associated with adverse effects of psychopathology and cognition.

New research on the prevalence of NMDA-receptor antibody encephalitis in first-episode and treatment-resistant psychosis

Treatment strategies for antipsychotic-induced hyperprolactinemia.

This form of nonsuicidal self-injury occurs within a spectrum of severity, and it is very likely that cases are both underreported and unpublished.

Despite the vast research conducted to better understand biological mechanisms underlying psychosis, people with psychotic disorders continue to suffer.

Those of us who have a diagnosis of a psychotic disorder are, above all, human beings. We are more than the disorder.

Psychotic disorders are potentially serious and enduring and have been seriously neglected in health systems worldwide. The good news is that better medium-term outcomes are now achievable.

Drs Zuardi and Crippa discuss the current stage of scientific evidence that supports the use of cannabidiol in schizophrenia, anxiety, and Parkinson disease. 

As we move forward from COVID-19, we take a look at noteworthy achievements that took place at lightning speed to inform response measures in future pandemics.

Familiarity with self-disorders is an indispensable tool in diagnosing a patient suspected for developing schizophrenia. Such knowledge improves communication with the patient and may serve as a starting point for therapeutic intervention.

Psychomotor speed may be a relevant target in studies of the immune system and its impact on the brain in patients with schizophrenia.

There is inadequate information regarding optimal antipsychotic doses in the treatment of acute schizophrenia that balance efficacy and safety. This article helps you get it right.

Policy initiatives can improve both physical and mental health care quality and outcomes for those with serious mental illnesses.

Artificial intelligence combined with electronic health records may detect FEP a year before onset in asymptomatic adults.

The mortality rate is unacceptably high in patient with serious mental illnesses. Several psychosocial interventions have been developed that may benefit these patients.

New (and not-so-new) insights on antipsychotics across a range of different measures of treatment response.

Schizophrenia and bipolar disorder are among the most serious psychiatric disorders and play a disproportionate role among individuals who end up homeless, incarcerated, and who die by suicide. Why the lack of research?

Parkinson disease psychosis is associated with worsening quality of life, greater caregiver distress, higher rates of institutionalization, increased mortality, and greater health care costs. The authors explore medical, psychosocial, and psychological factors associated with PD psychosis.

All current FDA-approved medications for the treatment of schizophrenia antagonize dopamine type 2 receptors-but that is where their similarity ends.

A number of factors affect treatment adherence, including the therapeutic alliance, perceived perceived lack of control, risk of dependence on medications, stigma associated with medication use, and more.

What are the benefits of using LAI antipsychotics? What are the major obstacles to adherence? Those questions and more in this podcast.